Volume 4.31 | Aug 9

Mammary Cell News 4.31 August 9, 2012
Mammary Cell News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human Cancers
Researchers identified an heat-shock factor 1 (HSF1)-regulated transcriptional program specific to highly malignant cells and distinct from heat shock. This HSF1 cancer program is active in breast, colon and lung tumors isolated directly from human patients and is strongly associated with metastasis and death. [Cell] Abstract | Press Release

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
PUBLICATIONS (Ranked by impact factor of the journal)


Biomarkers of Phenethyl Isothiocyanate-Mediated Mammary Cancer Chemoprevention in a Clinically Relevant Mouse Model
Researchers found that phenethyl isothiocyanate (PEITC) inhibited the growth of mammary cancers in a mouse model with similarities to human breast cancer progression. ATP synthase and transthyretin appear to be novel biomarkers associated with PEITC exposure. [J Natl Cancer Inst] Abstract

A DNA-Damage Selective Role for BRCA1 E3 Ligase in Claspin Ubiquitylation, CHK1 Activation, and DNA Repair
Scientists identified claspin as an in vivo substrate for the breast and ovarian cancer suppressor BRCA1 E3 ligase and suggested that its modification selectively triggers CHK1 activation for the homology-directed repair of a subset of genotoxic lesions. [Curr Biol] Abstract

TRPM7 Is Required for Breast Tumor Cell Metastasis
Scientists found that high levels of TRPM7 expression independently predict poor outcome in breast cancer patients and that it is functionally required for metastasis formation in a mouse xenograft model of human breast cancer. [Cancer Res] Abstract | Press Release

Flotillins as Regulators of ErbB2 Levels in Breast Cancer
Researchers showed that flotillins are involved in the stabilization of epithelial growth factor receptor 2 (ErbB2) at the plasma membrane. In SKBR3 breast cancer cells and breast cancer tissue, a positive correlation between flotillin and ErbB2 expression levels was demonstrated. [Oncogene] Abstract

LMTK3 Is Implicated in Endocrine Resistance via Multiple Signaling Pathways
Investigators found that inhibition of LMTK3 in a xenograft tamoxifen (Tam)-resistant breast cancer mouse model results in re-sensitization to Tam as demonstrated by a reduction in tumor volume. Data support a role for LMTK3 in both innate and acquired endocrine resistance in breast cancer. [Oncogene] Abstract

FGFR1 Is Amplified during the Progression of In Situ to Invasive Breast Carcinoma
Although amplification of HER2, C-MYC, CCND1 and FGFR1 has been reported in breast cancers, their role in the progression of in situ to invasive breast carcinoma is unclear. To investigate this question researchers compared the amplification frequencies of these genes in pure ductal carcinomas in situ (DCIS), DCIS associated with invasive carcinoma, and invasive carcinomas. [Breast Cancer Res] Abstract | Full Article

Homeodomain Containing Protein HOXB9 Regulates Expression of Growth and Angiogenic Factors, Facilitates Tumor Growth In Vitro and Is Overexpressed in Breast Cancer Tissue
Researchers investigated the biochemical roles of HOXB9 and its homeodomain in cell cycle progression and tumorigenesis. [FEBS J] Abstract

Furanodiene, a Natural Product, Inhibits Breast Cancer Growth Both In Vitro and In Vivo
The in vitro effects of furanodiene were examined on two human breast cancer cell lines, MCF-7 and MDA-MB-231 cells. The in vivo effect was determined with an MCF7 tumor xenograft model in nude mice. [Cell Physiol Biochem] Abstract | Full Article


A Phase I Study of Vinflunine in Combination with Trastuzumab for the Treatment for HER2-Positive Metastatic Breast Cancer
Scientists aimed to determine the recommended dose of vinflunine in combination with trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and to investigate potential pharmacokinetic interactions. [Cancer Chemother Pharmacol] Abstract

A Phase II Trial of Docetaxel and Carboplatin Administered Every Two Weeks as Preoperative Therapy for Stage II or III Breast Cancer: NCCTG Study N0338
Investigators conducted a multicenter phase II trial to assess the efficacy and toxicity of docetaxel and carboplatin combination as neoadjuvant therapy for stage II or III breast cancer. [Am J Clin Oncol] Abstract

50,000 scientists receive our newsletters. Do your colleagues? Click to share this newsletter now.


Lawson Research Suggests Breast Cancer Cells Have Discerning Tastes
A team of researchers from Lawson Health Research Institute and Western University have received $449,733 from the Canadian Breast Cancer Foundation to study cancer stem cells in hopes of uncovering the mystery behind metastasis. [Lawson Health Research Institute] Press Release

Fellow Honored for Breast Cancer Research
Oluwadamilola Fayanju, a clinical research fellow at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, has been named one of 16 recipients of the 2012 Breast Cancer Symposium Merit Award. [Siteman Cancer Center] Press Release

CPRIT’s Governing Board Ratifies $114 Million in New Cancer Awards
The Cancer Prevention and Research Institute of Texas (CPRIT) announced funding of more than $114 million to support a variety of cancer-fighting efforts in Texas. Highlights among the funded projects include two Phase II clinical trials studying interventions in breast cancer and acute myelogenous leukemia. [Cancer Prevention and Research Institute of Texas] Press Release

$2.5 Million to Fast-Track Breast Cancer Discoveries to the Clinic
A new collaborative center seeking to fast-track promising new discoveries in breast cancer to the clinic has been established with a $2.5 million grant from the National Health and Medical Research Council of Australia. [The Walter and Eliza Hall Institute of Medical Research] Press Release

Notice of Allowance of Breast Cancer Patent in Japan
DiaGenic has received notice of allowance of the family 3 patent application in Japan. The claims allowed the use of some important gene sequences in blood samples for detection and monitoring of breast cancer. The patent will be valid until 2025. [Business Wire] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW Keystone Symposia on Molecular and Cellular Biology: PI3-Kinase and Interplay with Other Signaling Pathways (X3)
February 24-March 1, 2013
Keystone, United States

our events page to see a complete list of events in the mammary cell community.


Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Associate Professor – Metastatic Breast Cancer (University of Colorado Comprehensive Cancer Center)

Postdoctoral Position – Breast Cancer (Albert Einstein College of Medicine)

Posdoctoral Position – Androgen Dependent Breast Cancer (The Institute of Cancer Research)

Posdoctoral Position(s) – Receptor Trafficking in Mammary Carcinogenesis (The Beatson Institute for Cancer Research)

Principal Investigator(s) – Cancer Research (National University of Singapore)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us